Training | 2016.07.14
Intrinsic Imaging Awarded Large Pivotal Phase III Oncology Trial for Metastatic Breast Cancer
Intrinsic Imaging, an FDA audited, ISO 9001, 13485 and 22301 certified imaging core lab has been awarded a global Phase III clinical trial designed to investigate the safety, tolerability and efficacy of a new oral chemotherapeutic for the treatment of metastatic breast cancer. Intrinsic Imaging will provide comprehensive imaging core lab services including protocol and charter development, site qualification, site training and management, image transfer, radiological review and data management.
(PRWeb July 14, 2016)
Read the full story at http://www.prweb.com/releases/2016/07/prweb13548171.htm
For more information, please visit
http://www.prweb.com/releases/2016/07/prweb13548171.htm
